Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus

Trial Profile

Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Maraviroc (Primary) ; Raltegravir (Primary) ; Emtricitabine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms No Nuc No Boost
  • Most Recent Events

    • 02 Sep 2016 Status changed from active, no longer recruiting to completed according to the results published in the Journal of Antimicrobial Chemotherapy.
    • 17 Jul 2016 Final results published in the Journal of Antimicrobial Chemotherapy.
    • 29 Dec 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top